Literature DB >> 18583923

Mesothelioma and asbestos-related pleural diseases.

Laurent Greillier1, Philippe Astoul.   

Abstract

At present, the use of asbestos is not regulated at a worldwide scale. Moreover, there is a latency period between asbestos exposure and the manifestations of asbestos-related diseases. Consequently, pulmonologists are still dealing with consequences of asbestos exposure, which mainly occur at the pleural surface. The aim of this review is to provide an overview of asbestos-related pleural diseases. We summarized the most relevant data for the diagnosis and the management of benign asbestos pleural effusions, pleural plaques, diffuse pleural thickening and rounded atelectasis. Special attention is dedicated to malignant pleural mesothelioma, given the challenging issues of this disease, the recent advances in its management and the dynamism of research in this area. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18583923     DOI: 10.1159/000127577

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  7 in total

1.  The physiological consequences of different distributions of diffuse pleural thickening on CT imaging.

Authors:  Duneesha de Fonseka; Anthony Edey; Louise Stadon; Jason Viner; Michael Darby; Nick A Maskell
Journal:  Br J Radiol       Date:  2017-07-14       Impact factor: 3.039

2.  Concentrations of asbestos fibers and metals in drinking water caused by natural crocidolite asbestos in the soil from a rural area.

Authors:  Binggan Wei; Bingxiong Ye; Jiangping Yu; Xianjie Jia; Biao Zhang; Xiuwu Zhang; Rongan Lu; Tingrong Dong; Linsheng Yang
Journal:  Environ Monit Assess       Date:  2012-08-10       Impact factor: 2.513

Review 3.  Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.

Authors:  Lisa Brusselmans; Lieselot Arnouts; Charissa Millevert; Joyce Vandersnickt; Jan P van Meerbeeck; Kevin Lamote
Journal:  Transl Lung Cancer Res       Date:  2018-10

4.  Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors.

Authors:  Xiaobo Cao; James Littlejohn; Charles Rodarte; Lidong Zhang; Benjamin Martino; Philip Rascoe; Kamran Hamid; Daniel Jupiter; W Roy Smythe
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

5.  Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients.

Authors:  Masashi Kobayashi; Cheng-Long Huang; Makoto Sonobe; Ryutaro Kikuchi; Masashi Ishikawa; Jiro Kitamura; Ryo Miyahara; Toshi Menju; Shotaro Iwakiri; Kazumi Itoi; Ryoji Yasumizu; Hiroshi Date
Journal:  Exp Ther Med       Date:  2012-03-12       Impact factor: 2.447

Review 6.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.

Authors:  Jun Kurai; Hiroki Chikumi; Kiyoshi Hashimoto; Miyako Takata; Takanori Sako; Kosuke Yamaguchi; Naoki Kinoshita; Masanari Watanabe; Hirokazu Touge; Haruhiko Makino; Tadashi Igishi; Hironobu Hamada; Seiji Yano; Eiji Shimizu
Journal:  Int J Oncol       Date:  2012-08-24       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.